Review Article

Laser-Assisted Subepithelial Keratectomy versus Laser In Situ Keratomileusis in Myopia: A Systematic Review and Meta-Analysis

Table 1

Characteristics of studies of LASEK versus LASIK included in the meta-analysis.

Trial (location)Laser machineDuration  (m)EyesMen (%)Age (years)  
Mean ± SD (range)
MRSE (D)  
Mean ± SD (range)
BCVA

Low to moderate

de Benito-Llopis et al. 2007 (Spain) [1]Technolas 217C3LASEK: 79
LASIK: 79
NA
NA
(19–46) 
(20–66)



Kaya et al. 2004 (Turkey) [2]LaserSight LSX6LASEK: 32
LASIK: 32
56.3 
56.3
total: .33
(19–36)



Kirwan and O’Keefe 2009 (Ireland) [3]Technolas 217z laser12LASEK: 50
LASIK: 65
NA 
NA
(20–52) 
(22–51)
(−1.1 to −8.6) 
(−1.5 to −6.5)

Chung et al. 2006 (Korea) [4]VISX Star S46LASEK: 70
LASIK: 70
NA 
NA
NA


Tobaigy et al. 2006 (USA) [5]Technolas 217z
VISX Star S2, S4
6LASEK: 122
LASIK: 122
58.5
51.9
(21–53) 
(21–61)

NS

Richter-Mueksch et al. 2005 (Austria) [6]Alcon LADARVision
Allegretto Wave 
excimer laser
3 wksLASEK: 26
LASIK: 26
52.9
47.1
(21–38) 
(20–37)
(−1.0 to −9.5) 
(−1.0 to −8.5)
NS

Tietjen et al. 2008 (German) [7]MEL 70G
Excimer laser
12LASEK: 30
LASIK: 30
50.0
50.0
total: 35 (18–52)
0.89
0.94

Teus et al. 2007 (Spain) [8]Technolas 217C3LASEK: 40
LASIK: 40
NA
NA
(20–42) 
(21–39)
(−2.00 to −6.40) 
(−2.00 to −6.40)
NA

Moderate to high

Kim et al. 2007 (Korea) [9]VISX Star S46LASEK: 148
LASIK: 87
33.0 
33.3

(−1.0 to −8.75) 
(−1.5 to −11.5)*


Buzzonetti et al. 2004 (Italy) [10]Alcon  
LADAR-Vision 4000
3LASEK: 18
LASIK: 18
NA
NA


NA

Kim et al. 2005 (Korea) [11]VISX Star24LASEK: 19
LASIK: 22
30.0
28.6
25 (23–29)
25 (24–27)
−8.50 (−6.81 to −9.69)
−7.49 (−7.25 to −9.69)
NA

Kim et al. 2004 (Korea) [12]Nidek EC-500012LASEK: 146
LASIK: 324
27.4 
32.9
(20–41) 
(21–39)
(−6.00 to −12.50) 
(−6.00 to −11.50)
NA

LASEK = laser-assisted subepithelial keratectomy, LASIK = laser in situ keratomileusis, MRSE = manifest refraction spherical equivalent, D = diopter, BCVA = best-corrected visual acuity, m = month, wks = weeks, NS = not significant, NA = not available.